Athens Research & Technology/Myeloperoxidase Enzyme Immunoassay Kit/K060H1/1 Plate

HumanMPOEIAKITFEATURES:

USE-MeasurehumanMPOinavarietyofmatrices
SAMPLE-Serum,Platelet-PoorHeparinPlasma,Saliva,UrineorTissueCultureMedia
SAMPLES/KIT-40induplicate
SENSITIVITY-0.068ng/mL
STABILITY-liquidreagentsstableat4°C
QUICKRESULTS-2.5HOURS

Myeloperoxidase(MPO)isatetramericheme-containingproteinabundantlyproducedinneutrophilgranulocyteswhereitplaysanimportantanti-microbialrole.DuringdegranulationMPOisreleasedintotheextracellularspace.There,aspartoftheneutrophils“respiratoryburst”,itproduceshypochlorousacidfromhydrogenperoxideandCl–.MPOalsouseshydrogenperoxidetooxidizetyrosinetothetyrosylrADIcal.Bothhypochlorousacidandtyrosylarecytotoxicandwhenpresentcankillbacteriaandotherpathogens.Hereditarydeficiencyofmyeloperoxidasepredisposesindividualstoimmunedeficiency.

StudieshaveshownanassociationbetweenelevatedMPOlevelsandcoronaryarterydisease,andin2003itwassuggestedthatMPOmayserveasasensitivepredictorofmyocardialinfarctioninpatientscomplainingofchestpain.SincethattimetheclinicalutilityofMPOtestingincardiacpatientshasbeensolidlyestablishedintheliteraturewithwellover100paperspublished.In2010thisclinicalapplicationwasfurtherrefinedbyadditionalstudieswhichdeterminedthatmeasuringbothMPOandC-reactiveprotein(CRP)providedmoreaccuratepredictionofmortalityriskthanmeasuringjustCRPalone.

References:
Zhangetal.(2001)Associationbetweenmyeloperoxidaselevelsandriskofcoronaryarterydisease;JAMA,2862135
Brennanetal.(2003)Prognosticvalueofmyeloperoxidaseinpatientswithchestpain;NewEngl.J.Med.,3491595
Heslopetal.(2010)MyeloperoxidaseandC-reactiveproteinhavecombinedutilityforlong-termpredictionofcardiovascularmortalityaftercoronaryangiography;J.Am.Coll.OfCardiol.551102

AthensResearchandTechnology(ART)haspartneredwithARBORASSAYStoofferthebestMPOEIAkitavailable.ThefoundersandtopscientistsfromArborAssayshavebeenresearchinganddevelopinghighqualityassaykitssince1982,soARTutilizedour30yearsofexperienceadvancingandperfectingtechniquesinproteinpurificationtoisolateasuperiorqualityantigenwhichtheArborAssaysteamthendevelopedintoatopofthelineEIAfeaturingauniqueantibodypairingalongwithcarefuloptimizationandtheirtrademarkexceptionalqualitycontrol.TheAthensResearchandTechnology/ArborAssayshumanMPOEIAkithasbeenvalidatedforserum,platelet-poorheparinplasma,saliva,urineandtissueculturemediawithresultsinjust2.5hoursandasensitivityof0.68ng/ml.Thekitisavailableforpurchasefromeithercompany(ArborAssayscat.#K060-H1,AthensResearchandTechnologycat.#K060-H1).

RelatedProducts:

AllopregnanoloneEIA&CLIA–K044-H&K044-C
AtrialNatriureticPeptide(ANP)EIA–K026-H
Endothelin(ET-1)EIAKit–K045-H1
NitricOxide(NO)ColorimetricDetectionKit–K023-H1
HemoglobinColorimetricDetectionKit–K013-H1
ProstaglandinE2(PGE2)Multi-FormatKits–K051-H
ProteinKinaseA(PKA)ActivityKit–K027-H1
ST2HumanEIAKit–K055-H1

AthensResearchandTechnologyReagents:
Myeloperoxidase,HumanNeutrophils–16-14-130000
HighDensityLipoprotein(HDL),Human,Plasma–12-16-080412
Ceruloplasmin,HumanPlasma–16-16-030518
SuperoxideDismutase(SOD),HumanErythrocytes–16-05-191504
Elastase,HumanNeutrophils–16-14-051200
EosinophilPeroxidase(EPO),HumanEosinophils–16-15-160518
Lactoferrin,HumanMilk–16-13-120103